Computational insights into overcoming resistance mechanisms in targeted therapies for advanced breast cancer: focus on EGFR and HER2 co-inhibition

References

• Alsaady, I. M., Bajrai, L. H., Alandijany, T. A., Gattan, H. S., El-Daly, M. M., Altwaim, S. A., Alqawas, R. T., Dwivedi, V. D., & Azhar, E. I. (2023). Cheminformatics strategies unlock Marburg virus VP35 inhibitors from natural compound library. Viruses, 15(8), 1739. https://doi.org/10.3390/v15081739
   PubMed Web of Science ®Google Scholar
• Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J. R., Cardoso, F., Siesling, S., & Soerjomataram, I. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast (Edinburgh, Scotland), 66, 15–23. https://doi.org/10.1016/j.breast.2022.08.010
   PubMed Web of Science ®Google Scholar
• Bai, X., Sun, P., Wang, X., Long, C., Liao, S., Dang, S., Zhuang, S., Du, Y., Zhang, X., Li, N., He, K., & Zhang, Z. (2023). Structure and dynamics of the EGFR/HER2 heterodimer. Cell Discovery, 9(1), 1-16. https://doi.org/10.1038/s41421-023-00523-5
   Web of Science ®Google Scholar
• Bank, R. P. D. (n.d.). RCSB PDB - 8HGO: The EGF-bound EGFR/HER2 ectodomain complex. Retrieved October 11, 2023, from https://www.rcsb.org/structure/8HGO
   Google Scholar
• Berendsen, H. J. C., van der Spoel, D., & van Drunen, R. (1995). GROMACS: A message-passing parallel molecular dynamics implementation. Computer Physics Communications, 91(1–3), 43–56. https://doi.org/10.1016/0010-4655(95)00042-E
   Web of Science ®Google Scholar
• Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., & Bourne, P. E. (2000). The protein data bank. Nucleic Acids Research, 28(1), 235–242. https://doi.org/10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Blasquez, L., Bouzinba‐Segard, H., Bourdoulous, S., & Faure, C. (2023). Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2‐positive cancers. Molecular Oncology, 17(10), 1981–1999. https://doi.org/10.1002/1878-0261.13419
   PubMed Web of Science ®Google Scholar
• Borrero-García, L. D., del Mar Maldonado, M., Medina-Velázquez, J., Troche-Torres, A. L., Velazquez, L., Grafals-Ruiz, N., & Dharmawardhane, S. (2021). Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer. BMC Cancer, 21(1), 652. https://doi.org/10.1186/s12885-021-08366-7
   PubMed Web of Science ®Google Scholar
• Brady, G. P., & Stouten, P. F. (2000). Fast prediction and visualization of protein binding pockets with PASS. Journal of Computer-Aided Molecular Design, 14(4), 383–401. https://doi.org/10.1023/a:1008124202956
   PubMed Web of Science ®Google Scholar
• Bussi, G., Donadio, D., & Parrinello, M. (2007). Canonical sampling through velocity rescaling. The Journal of Chemical Physics, 126(1), 014101. https://doi.org/10.1063/1.2408420
   PubMed Web of Science ®Google Scholar
• Dakroub, R., Huard, S., Hajj-Younes, Y., Suresh, S., Badran, B., Fayyad-Kazan, H., & Dubois, T. (2023). Therapeutic advantage of targeting PRMT5 in combination with chemotherapies or EGFR/HER2 inhibitors in triple-negative breast cancers. Breast Cancer (Dove Medical Press), 15, 785–799. https://doi.org/10.2147/BCTT.S430513
   PubMed Web of Science ®Google Scholar
• DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Goding Sauer, A., Jemal, A., & Siegel, R. L. (2019). Breast cancer statistics, 2019. CA: A Cancer Journal for Clinicians, 69(6), 438–451. https://doi.org/10.3322/caac.21583
   PubMed Web of Science ®Google Scholar
• Dhiwar, P. S., Purawarga Matada, G. S., Pal, R., Singh, E., Ghara, A., Maji, L., Sengupta, S., & Andhale, G. (2023). An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: A brief review. Journal of Biomolecular Structure & Dynamics, 1–18. https://doi.org/10.1080/07391102.2023.2204351
   PubMed Web of Science ®Google Scholar
• Doherty, J. K., Bond, C., Jardim, A., Adelman, J. P., & Clinton, G. M. (1999). The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proceedings of the National Academy of Sciences of the United States of America, 96(19), 10869–10874. https://doi.org/10.1073/pnas.96.19.10869
   PubMed Web of Science ®Google Scholar
• Eberhardt, J., Santos-Martins, D., Tillack, A. F., & Forli, S. (2021). AutoDock Vina 1.2.0: New docking methods, expanded force field, and python bindings. Journal of Chemical Information and Modeling, 61(8), 3891–3898. https://doi.org/10.1021/acs.jcim.1c00203
   PubMed Web of Science ®Google Scholar
• Fakhry, M. M., Mattar, A. A., Alsulaimany, M., Al-Olayan, E. M., Al-Rashood, S. T., & Abdel-Aziz, H. A. (2023). New thiazolyl-pyrazoline derivatives as potential dual EGFR/HER2 inhibitors: Design, synthesis, anticancer activity evaluation and in silico study. Molecules (Basel, Switzerland), 28(21), 7455. https://doi.org/10.3390/molecules28217455
   PubMed Web of Science ®Google Scholar
• Fogolari, F., Brigo, A., & Molinari, H. (2002). The Poisson-Boltzmann equation for biomolecular electrostatics: A tool for structural biology. Journal of Molecular Recognition: JMR, 15(6), 377–392. https://doi.org/10.1002/jmr.577
   PubMed Web of Science ®Google Scholar
• Hess, B., Kutzner, C., van der Spoel, D., & Lindahl, E. (2008). GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. Journal of Chemical Theory and Computation, 4(3), 435–447. https://doi.org/10.1021/ct700301q
   PubMed Web of Science ®Google Scholar
• Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S., & Coleman, R. G. (2012). ZINC: A free tool to discover chemistry for biology. Journal of Chemical Information and Modeling, 52(7), 1757–1768. https://doi.org/10.1021/ci3001277
   PubMed Web of Science ®Google Scholar
• Ishikawa, T., Seto, M., Banno, H., Kawakita, Y., Oorui, M., Taniguchi, T., Ohta, Y., Tamura, T., Nakayama, A., Miki, H., Kamiguchi, H., Tanaka, T., Habuka, N., Sogabe, S., Yano, J., Aertgeerts, K., & Kamiyama, K. (2011). Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2- d] pyrimidine Scaffold. Journal of Medicinal Chemistry, 54(23), 8030–8050. https://doi.org/10.1021/jm2008634
   PubMed Web of Science ®Google Scholar
• Jakalian, A., Jack, D. B., & Bayly, C. I. (2002). Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. Journal of Computational Chemistry, 23(16), 1623–1641. https://doi.org/10.1002/jcc.10128
   PubMed Web of Science ®Google Scholar
• Jeon, M., You, D., Bae, S. Y., Kim, S. W., Nam, S. J., Kim, H. H., Kim, S., & Lee, J. E. (2017). Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction. Oncotarget, 8(31), 50570–50581. https://doi.org/10.18632/oncotarget.10843
   PubMedGoogle Scholar
• Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., & Yarden, Y. (1996). ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer. The EMBO Journal, 15(2), 254–264. https://doi.org/10.1002/j.1460-2075.1996.tb00356.x
   PubMed Web of Science ®Google Scholar
• Kawakita, Y., Miwa, K., Seto, M., Banno, H., Ohta, Y., Tamura, T., Yusa, T., Miki, H., Kamiguchi, H., Ikeda, Y., Tanaka, T., Kamiyama, K., & Ishikawa, T. (2012). Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: Improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy. Bioorganic & Medicinal Chemistry, 20(20), 6171–6180. https://doi.org/10.1016/j.bmc.2012.08.002
   PubMed Web of Science ®Google Scholar
• Kokai, Y., Myers, J. N., Wada, T., Brown, V. I., LeVea, C. M., Davis, J. G., Dobashi, K., & Greene, M. I. (1989). Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell, 58(2), 287–292. https://doi.org/10.1016/0092-8674(89)90843-X
   PubMed Web of Science ®Google Scholar
• Kumari, R., Kumar, R., & Lynn, A., Open Source Drug Discovery Consortium. (2014). g_mmpbsa—A GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54(7), 1951–1962. https://doi.org/10.1021/ci500020m
   PubMed Web of Science ®Google Scholar
• Lindorff-Larsen, K., Piana, S., Palmo, K., Maragakis, P., Klepeis, J. L., Dror, R. O., & Shaw, D. E. (2010). Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins, 78(8), 1950–1958. https://doi.org/10.1002/prot.22711
   PubMed Web of Science ®Google Scholar
• Maisuradze, G. G., Liwo, A., & Scheraga, H. A. (2010). Relation between free energy landscapes of proteins and dynamics. Journal of Chemical Theory and Computation, 6(2), 583–595. https://doi.org/10.1021/ct9005745
   PubMed Web of Science ®Google Scholar
• Mongan, J., Simmerling, C., McCammon, J. A., Case, D. A., & Onufriev, A. (2007). Generalized born model with a simple, robust molecular volume correction. Journal of Chemical Theory and Computation, 3(1), 156–169. https://doi.org/10.1021/ct600085e
   PubMed Web of Science ®Google Scholar
• Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/10.1002/jcc.21256
   PubMed Web of Science ®Google Scholar
• Naishima, N. L., Faizan, S., Raju, R. M., Sruthi, A. S. V. L., Veena, N., Sharma, G. K., Vasanth, K. S., Shivaraju, V. K., Ramu, R., & Kumar, B. P. (2023). Design, synthesis, analysis, evaluation of cytotoxicity against MCF-7 breast cancer cells, 3D QSAR studies and EGFR, HER2 inhibition studies on novel biginelli 1, 4-dihydropyrimidines. Journal of Molecular Structure, 1277, 134848. https://doi.org/10.1016/j.molstruc.2022.134848
   Web of Science ®Google Scholar
• Parrinello, M., & Rahman, A. (1981). Polymorphic transitions in single crystals: A new molecular dynamics method. Journal of Applied Physics, 52(12), 7182–7190. https://doi.org/10.1063/1.328693
   Web of Science ®Google Scholar
• Ross, J. S., Fletcher, J. A., Bloom, K. J., Linette, G. P., Stec, J., Symmans, W. F., Pusztai, L., & Hortobagyi, G. N. (2004). Targeted therapy in breast cancer. Molecular & Cellular Proteomics: MCP, 3(4), 379–398. https://doi.org/10.1074/mcp.R400001-MCP200
   PubMed Web of Science ®Google Scholar
• Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., & Bloom, K. J. (2003). The HER-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. The Oncologist, 8(4), 307–325. https://doi.org/10.1634/theoncologist.8-4-307
   PubMed Web of Science ®Google Scholar
• Saibu, O. A., Singh, G., Olugbodi, S. A., Oluwafemi, A. T., Ajayi, T. M., Hammed, S. O., Oladipo, O. O., Odunitan, T. T., & Omoboyowa, D. A. (2023). Identification of HER2 inhibitors from curcumin derivatives using combination of in silico screening and molecular dynamics simulation. Journal of Biomolecular Structure & Dynamics, 41(21), 12328–12337. https://doi.org/10.1080/07391102.2023.2175260
   PubMedGoogle Scholar
• Shukla, D., Alanazi, A. M., Panda, S. P., Dwivedi, V. D., & Kamal, M. A. (2023). Unveiling the antiviral potential of Plant compounds from the Meliaceae family against the Zika virus through QSAR modeling and MD simulation analysis. Journal of Biomolecular Structure & Dynamics, 1–16. https://doi.org/10.1080/07391102.2023.2259498
   Web of Science ®Google Scholar
• Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., & Press, M. F. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (New York, NY), 244(4905), 707–712. https://doi.org/10.1126/science.2470152
   Google Scholar
• Sousa da Silva, A. W., & Vranken, W. F. (2012). ACPYPE - AnteChamber PYthon Parser interfacE. BMC Research Notes, 5(1), 367. https://doi.org/10.1186/1756-0500-5-367
   PubMedGoogle Scholar
• Street, W. (n.d.). Breast cancer facts & figures 2017–2018.
   Google Scholar
• Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., Ouyang, L., & Li, W. (2022). Development of dual inhibitors targeting epidermal growth factor receptor in cancer therapy. Journal of Medicinal Chemistry, 65(7), 5149–5183. https://doi.org/10.1021/acs.jmedchem.1c01714
   PubMed Web of Science ®Google Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/10.1002/jcc.21334
   PubMed Web of Science ®Google Scholar
• Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004). Development and testing of a general amber force field. Journal of Computational Chemistry, 25(9), 1157–1174. https://doi.org/10.1002/jcc.20035
   PubMed Web of Science ®Google Scholar
• Watkins, E. J. (2019). Overview of breast cancer. JAAPA: Official Journal of the American Academy of Physician Assistants, 32(10), 13–17. https://doi.org/10.1097/01.JAA.0000580524.95733.3d
   PubMedGoogle Scholar
• Webb, B., & Sali, A. (2016). Comparative protein structure modeling using MODELLER. Current Protocols in Bioinformatics, 54(1), 5.6.1–5.6.37. https://doi.org/10.1002/cpbi.3
   PubMedGoogle Scholar
• World Health Organization. (2023). Breast cancer report by WHO. https://www.who.int/news-room/fact-sheets/detail/breast-cancer
   Google Scholar
• Yang, Y., Choppavarapu, L., Fang, K., Naeini, A. S., Nosirov, B., Li, J., Yang, K., He, Z., Zhou, Y., Schiff, R., Li, R., Hu, Y., Wang, J., & Jin, V. X. (2020). The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells. Biochimica et Biophysica Acta. Gene Regulatory Mechanisms, 1863(11), 194631. https://doi.org/10.1016/j.bbagrm.2020.194631
   PubMed Web of Science ®Google Scholar
• Yarden, Y. (2001). Biology of HER2 and its importance in breast cancer. Oncology, 61(Suppl. 2), 1–13. https://doi.org/10.1159/000055396
   PubMed Web of Science ®Google Scholar
• Zubair, T., & Bandyopadhyay, D. (2023). Small molecule EGFR inhibitors as anti-cancer agents: Discovery, mechanisms of action, and opportunities. International Journal of Molecular Sciences, 24(3), 2651. https://doi.org/10.3390/ijms24032651
   PubMed Web of Science ®Google Scholar